SEC Comment Letter for Akari Therapeutics Plc (AKTX) (CIK 0001541157) (AKTX) — Aug 12, 2019
Akari Therapeutics Plc (AKTX) (CIK 0001541157)
Date: Aug. 12, 2019 · CIK: 0001541157 · Accession: 0000000000-19-012340
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233048
Letter
August 12, 2019 Clive Richardson Interim Chief Executive Officer Akari Therapeutics, Plc 75/76 Wimpole Street London W1G 9RT United Kingdom Re:Akari Therapeutics, Plc Registration Statement on Form F-1 Filed August 6, 2019 File No. 333-233048 Dear Mr. Richardson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Gary Emmanuel, Esq.
Show Raw Text
August 12, 2019
Clive Richardson
Interim Chief Executive Officer
Akari Therapeutics, Plc
75/76 Wimpole Street
London W1G 9RT
United Kingdom
Re:Akari Therapeutics, Plc
Registration Statement on Form F-1
Filed August 6, 2019
File No. 333-233048
Dear Mr. Richardson:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Gary Emmanuel, Esq.